A Comparative Study for Non-Hodgkin's Lymphoma in Hepatitis B Virus Carriers
Non-Hodgkin's Lymphoma
About this trial
This is an interventional treatment trial for Non-Hodgkin's Lymphoma
Eligibility Criteria
Inclusion Criteria: Histologically proven NHL, and for which intensive chemotherapy is considered treatment-of-choice. HBsAg-positive. No previous chemotherapy and radiotherapy. No concurrent radiotherapy. AGC ≧ 2,000/mm3, Platelet ≧ 100,000/mm3 of peripheral blood. Total bilirubin ≦ 2.5 mg/dl. Alanine aminotransferase (SGPT) < 200 I.U/L Serum creatinine ≦1.5 mg/dl Blood urea nitrogen (BUN) ≦ 25 mg/dl Objectively measurable or evaluable disease Signed informed consent Exclusion Criteria: Age > 75 years, or Age < 15 years Pregnant or breast-feeding women. Patients with history of brain metastasis or CNS involvement. Child's class B or C in patients with liver cirrhosis. Impaired cardiac function with NYHA (New York Heart Association) classification ≧ GrII. Concurrent glucocorticoids use (for other reasons). The conventional use of glucocorticoids for antiemetic purpose is also not allowed.
Sites / Locations
- National Taiwan University Hospital